Literature DB >> 35029787

Safety Evaluation of Goat Milk Added with the Prebiotic Inulin Fermented with the Potentially Probiotic Native Culture Limosilactobacillus mucosae CNPC007 in Co-culture with Streptococcus thermophilus QGE: Analysis of Acute and Repeated Dose Oral Toxicity.

Áurea Marcela de Souza Pereira1, Larissa Caroline de Almeida Sousa Lima2, Laisa Wanessa Santos Lima2, Tamires Meira Menezes2, Ângela Magalhães Vieira3, Eryvelton de Souza Franco4, Silvânia Tavares Paz5, Carina Scanoni Maia5, Antônio Sílvio do Egito6, Karina Maria Olbrich Dos Santos7, Flávia Carolina Alonso Buriti8, Maria Bernadete de Sousa Maia2.   

Abstract

Despite functional goat milk products having emerged due to their importance for human nutrition and health, few studies have assessed the safety of consumption of goat dairy products containing potentially probiotic autochthonous lactic acid bacteria supplemented with prebiotic carbohydrates. Aiming this field, this study evaluated the safety of goat's milk fermented with Streptococcus thermophilus QGE, the autochthonous Limosilactobacillus mucosae CNPC007 culture, and the prebiotic inulin, through single- and repeated-dose oral toxicity tests (SDT and RDT, respectively) in animals. Ten female Swiss Webster mice were used for SDT evaluation - 2 groups, SDTc (20 mL/kg of filtered water) and SDTt (20 mL/kg of fermented milk) - and 40 Wistar rats for RDT - RDT3, RDT6, and RDT12 (treated with fermented milk at doses of 3 mL/kg, 6 mL/kg, and 12 mL/kg, respectively) and also RDTc (12 mL/kg of filtered water). For SDT, no signs of mortality or toxicity were observed, and the animals maintained the expected weight gain and feed intake. The RDT trials did not show mortality or signs of toxicity, as well as no change in body weight and organs, in the hematological and biochemical parameters, and also in relation to morphology and histology. Since the fermented milk did not cause any toxic effect in the conditions evaluated, it can be said that its no-adverse effect level (NOAEL) was considered to be higher than 20 mL/kg/day. Thus, the fermented milk with L. mucosae CNPC007 and inulin was considered to be of low toxicity, safe for use in rodents, and allowed for use in further studies.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Autochthonous lactic acid bacteria; Goat dairy products; In vivo assay; No-adverse effect level; Prebiotics

Year:  2022        PMID: 35029787     DOI: 10.1007/s12602-021-09898-x

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  20 in total

Review 1.  Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.

Authors:  Glenn R Gibson; Robert Hutkins; Mary Ellen Sanders; Susan L Prescott; Raylene A Reimer; Seppo J Salminen; Karen Scott; Catherine Stanton; Kelly S Swanson; Patrice D Cani; Kristin Verbeke; Gregor Reid
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-14       Impact factor: 46.802

Review 2.  How do probiotics and prebiotics function at distant sites?

Authors:  G Reid; T Abrahamsson; M Bailey; L B Bindels; R Bubnov; K Ganguli; C Martoni; C O'Neill; H M Savignac; C Stanton; N Ship; M Surette; K Tuohy; S van Hemert
Journal:  Benef Microbes       Date:  2017-07-20       Impact factor: 4.205

Review 3.  From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course?

Authors:  Luigi Barrea; Giovanna Muscogiuri; Giuseppe Annunziata; Daniela Laudisio; Gabriella Pugliese; Ciro Salzano; Annamaria Colao; Silvia Savastano
Journal:  Hormones (Athens)       Date:  2019-03-06       Impact factor: 2.885

4.  Dietary inulin decreases circulating ceramides by suppressing neutral sphingomyelinase expression and activity in mice.

Authors:  Pan Deng; Jessie B Hoffman; Michael C Petriello; Chun-Yan Wang; Xu-Sheng Li; Maria P Kraemer; Andrew J Morris; Bernhard Hennig
Journal:  J Lipid Res       Date:  2019-10-11       Impact factor: 5.922

5.  Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial.

Authors:  Rikke Meineche Schmidt; Rikke Pilmann Laursen; Signe Bruun; Anni Larnkjaer; Christian Mølgaard; Kim F Michaelsen; Arne Høst
Journal:  Pediatr Allergy Immunol       Date:  2019-02-21       Impact factor: 6.377

6.  Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice.

Authors:  Jing Xue; Xiaorong Li; Ping Liu; Ke Li; Liping Sha; Xiaoli Yang; Lili Zhu; Zhen Wang; Youping Dong; Li Zhang; Hong Lei; Xiaoxia Zhang; Xiaoying Dong; Hao Wang
Journal:  Endocr J       Date:  2019-07-03       Impact factor: 2.349

7.  Probiotic and synbiotic supplementation could improve metabolic syndrome in prediabetic adults: A randomized controlled trial.

Authors:  Nazila Kassaian; Awat Feizi; Ashraf Aminorroaya; Masoud Amini
Journal:  Diabetes Metab Syndr       Date:  2018-07-30

8.  The effect of inulin and resistant maltodextrin on weight loss during energy restriction: a randomised, placebo-controlled, double-blinded intervention.

Authors:  Anne Lundby Hess; Alfonso Benítez-Páez; Trine Blædel; Lesli Hingstrup Larsen; Jose Ramón Iglesias; Carmen Madera; Yolanda Sanz; Thomas Meinert Larsen
Journal:  Eur J Nutr       Date:  2019-10-11       Impact factor: 5.614

9.  Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.

Authors:  Yunhuan Liu; Kefei Chen; Fengyuan Li; Zelin Gu; Qi Liu; Liqing He; Tuo Shao; Qing Song; Fenxia Zhu; Lihua Zhang; Mengwei Jiang; Yun Zhou; Shirish Barve; Xiang Zhang; Craig J McClain; Wenke Feng
Journal:  Hepatology       Date:  2020-03-16       Impact factor: 17.425

10.  Probiotics and immunity: provisional role for personalized diets and disease prevention.

Authors:  Rostyslav V Bubnov; Mykola Ya Spivak; Liudmyla M Lazarenko; Alojz Bomba; Nadiya V Boyko
Journal:  EPMA J       Date:  2015-07-14       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.